Enterprise News for 2010



December 1, 2010
Freescale Semiconductor Implements Enviance's Environmental ERP Solution to Reduce Environmental Risk
Freescale Replaces Client Server Software with Enviance to Achieve Greater Emissions Awareness and Flexibility to Manage Growing Environmental Priorities. CARLSBAD, Calif. November 30, 2010 Enviance, Inc., a global provider of Environmental ERP solutions that measure, manage, report and reduce environmental and regulatory risks, announced today that Freescale Semiconductor has selected Enviance as its proprietary solution to measure and report compliance data on all compliance areas including water, air and emissions. Freescale replaced its existing vendor with the Enviance cloud-based platform in order to manage the emissions requirements of multiple facilities in one centralized system.

November 15, 2010
Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements
CUPID Trial Data Presented Today at American Heart Association Conference. Chicago, November 15, 2010 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

November 10, 2010
Enterprise Partners Portfolio Firm Heads To Market
November 10, 2010 - socaltech.com - One of the portfolio firms of San Diego-based venture capital firm Enterprise Partners, Complete Genomics is set to debut on the market Thursday, after pricing its IPO this evening. According to a filing from Complete Genomics, it will sell 6 million shares at $9.00 per share, below an earlier estimated range of $12.00 to $14.00 per share for the company. Complete Genomics will trade on the NASDAQ Global Market as GNOM. Enterprise Partners owns about 14.8 percent of Complete Genomics. The IPO marks the second major acquisition in Enterprise Partners' portfolio this year; the firm also was an investor in Targegen, which was acquired by Sanofi-aventis in June.

October 20, 2010
XIFIN Ranked as a Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500
San Diego, CA October 20, 2010 XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, today announced that it ranked on the Technology Fast 500, Deloittes ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 20052009.

October 18, 2010
Specific Media Acquires Digital Video Leader BBE
Irvine, CA and New York, NY 18 October 2010 Specific Media, the worlds largest independent media platform, today announced that it has acquired Broadband Enterprises (BBE), a premier online video provider. Founded in 2004, BBE is a video advertising company that helps brands to monetize, track and produce video across all digital platforms. The deal recently closed for an undisclosed amount.

August 31, 2010
Dimension Data selects Enviance to manage energy and waste reduction goals
New York August 31, 2010 - Dimension Data, the $4 billion global IT services and solutions provider, has taken another step in its strategy to report its carbon footprint, and track energy and
waste reduction goals. The company said today that it will centralize its carbon footprint reporting, and provide organization-wide monitoring of its carbon and waste reduction goals. Merle Singer, Dimension Datas Global Director Sustainability said, Currently, Dimension Data voluntarily reports its carbon footprint as it strives to monitor the impact of its operations on the environment. Taking the next step and implementing leading-edge software will allow us to further
monitor, measure and manage our environmental impact.

August 30, 2010
Tina Nova - Top 10 Women in Biotech
It's a well-worn clich that men dominate the top ranks of the biotech industry. But over the past decade a group of extraordinary women has put that clich to the test. Perhaps one of the most interesting aspects of our selection of 10 women who have excelled in the industry is that there were so many outstanding women in biotechnology to choose from.

August 30, 2010
XIFIN Named to Inc. 5000 for Fourth Consecutive Year
San Diego, CA August 30, 2010 - XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, today announced that the company has been named to the 2010 Inc. 5000 list of fastest-growing private companies for the fourth consecutive year, ranking 1,447th. The company ranked No. 96 in Top Software Companies, and No. 34 in Top Companies in the San Diego Metro Area. The list is widely regarded to include the most innovative and entrepreneurial companies in the nation.

August 19, 2010
Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsuit
MOUNTAIN VIEW, Calif. Aug. 19, 2010 Complete Genomics announced today that it has raised $39 million in its Series E funding round. New investor Sands Capital led this round of financing and was joined by existing investors Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital and Enterprise Partners. Complete Genomics also reported that it is evaluating the lawsuit alleging patent infringement which was filed against it by Illumina, Inc. and Solexa, Inc., an entity acquired by Illumina, on Aug. 3, 2010 in the U.S. District Court in Delaware.

August 12, 2010
Devicescape Enters Wi-Fi Location Business
Devicescape will offer SoftGPS, another way for device makers to obtain coordinates for mobile equipment on the go, GPS or no: I've written before that Devicescape and Skyhook Wireless are two of my favorite companies in the back-end Wi-Fi space because what they do is so clever. Both have been around for years; both are seeing the payoff for consistently working towards intelligible goals. And both rely on their software or data being used by other firms.

August 3, 2010
Complete Genomics S-1 Filing Media Coverage Report

July 30, 2010
Complete Genomics, Inc. Files Registration Statement for Proposed Initial Public Offering
MOUNTAIN VIEW, Calif. July 30, 2010 Complete Genomics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc.

June 30, 2010
Sanofi-aventis To Acquire TargeGen, Inc.
San Diego, CA June 30, 2010- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN and NYSE: SNY). Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

May 30, 2010
Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients
CUPID Trial Data Presented Today as Late-Breaker at Heart Failure 2010, the Annual Meeting of the Heart Failure Association of the European Society of Cardiology. BERLIN, May 30, 2010 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

May 26, 2010
Genentech Uses Complete Genomics Human Genome Sequencing Service to Compare Tumor and Normal Genome
MOUNTAIN VIEW, Calif. May 26, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), used the companys sequencing, bioinformatics and analytics services to sequence and compare a patients primary lung tumor and adjacent normal tissue. Tumor-normal pairs like this allow researchers to compare the patients genome before and after it was altered by the cancer; the patients normal genome serves as the ideal control. This is the first time that such a comparison has been made across the whole genome for a lung cancer patient. Genentechs findings will be published online in Nature later today in a paper titled The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

April 28, 2010
Celladon Corp. Announces that MYDICAR Meets Primary Endpoint in Phase 2 Trial for Treatment of Advanced Heart Failure
LAJOLLA, Calif., April 28, 2010 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that its first Phase 2 trial with MYDICAR for the treatment of advanced heart failure has met the prospectively defined safety and efficacy endpoints for the trial as defined in the Phase 2 clinical trial protocol. Study Results Demonstrate Favorable Treatment Effects with Genetically Targeted Enzyme Replacement Therapy.

March 23, 2010
Celladon Corporation Receives Notice of Allowance by U.S. Patent and Trademark Office for Broad Patent Covering Lead Drug Candidate MYDICAR
Patent to Cover Use of All Adeno-Associated Viral Vectors and Routes of Administration for Delivery of SERCA2a Gene for Treatment of Heart Failure. LA JOLLA, Calif., March 23, 2010 Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the companys lead drug candidate MYDICAR, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

March 18, 2010
Founding CEO Tina "Super" Nova Keeps Genoptix On a Roll
It must be nice to be the CEO of a life sciences company that sells itself. When Tina Nova stepped up to the microphone at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, CA, yesterday, the Genoptix CEO was playing to a nearly full house. Investors and analysts occupied all but two or three seats, which wasnt the case in many of the other presentations given on the last day of the three-day conference (even though it drew a record total of more than 3,000 attendees, according to organizers).

March 16, 2010
ReliOn E-200 Fuel Cell System Named as Finalist in CTIA E-Tech Awards
Spokane, Wash.: Fuel cell provider ReliOns E-200 hydrogen fuel cell system has been named a finalist in the Green category in the CTIA Emerging Technology (E-Tech) Awards. CTIAs fifth annual E-Tech Awards program recognizes products in 15 categories in the areas of mobile consumer electronics, luxury mobile, applications, enterprise, green solutions and network technology. International CTIA WIRELESS 2010 will take place March 23-25 at the Las Vegas Convention Center.

March 10, 2010
Institute for Systems Biology Uses Complete Genomics Human Genome Sequencing Service to Verify Gene Responsible For Miller Syndrome
MOUNTAIN VIEW, Calif. March 10, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that the Institute for Systems Biology (ISB) employed Complete Genomics human genome sequencing service to sequence a family quartet to determine the depth of genetic information possible in analyzing a full familys sequence, and to verify the gene responsible for Miller syndrome, a rare craniofacial disorder. Results from this collaboration will be published later today in the journal Science; the manuscript is titled Analysis of Genetic Inheritance in a Family Quartet by Whole Genome Sequencing.

March 9, 2010
CGI ranked #7 on Wall Street Journals list of The Top 50 Venture-Backed Companies
Sizing Up Promising Young Firms - Venture capitalists, the investors who supply start-up money to promising young companies, are always looking for the next big thingwhether it's a hot new gadget, game or medical breakthrough. Amid a shakeout caused by poor returns, VCs are having a tough time these days, but many of them are still nurturing inventors and entrepreneurs.

There are some 10,000 privately held, venture-backed companies in the U.S. To pick the 50 of them with the greatest potential, a team from research firm VentureSource, a unit of Wall Street Journal owner News Corp., applied a strict set of standards.

February 25, 2010
Complete Genomics Named One of the 50 Most Innovative Companies of 2010 by Technology Review
MOUNTAIN VIEW, Calif. Feb. 25, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that it has been included in MIT Technology Reviews TR50, the publications 2010 list of the 50 most innovative companies in the world. The TR50 list is our selection of companies that show the most impressive innovation in commercializing new technologies, said Jason Pontin, editor in chief and publisher of Technology Review. In selecting the years top innovative companies, TR50 judges reviewed the most important inventions and breakthroughs in several categories, including biomedicine. Complete Genomics received a place on the TR50 list for its ability to provide human genome sequencing and analysis efficiently and affordably.

February 22, 2010
Complete Genomics Announces New Customers and Substantial Orders for Its Large-Scale Human Genome Sequencing Service
MOUNTAIN VIEW, Calif. Feb. 22, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today reported on its commercial success. Complete Genomics now has more than 30 customers and a strong pipeline with booked orders exceeding 500 human genomes. Its new customers, which range from academic institutions and genome centers to pharmaceutical companies, include Eli Lilly, the University of North Carolina, the Institute of Molecular Medicine at the University of Texas Health Science Center at Houston, Childrens Hospital of Philadelphia, Institute of Cancer Research UK, Academic Medical Center (AMC) University of Amsterdam, and the Department of Bioinformatics, Erasmus Medical Centre in Rotterdam, the Netherlands.
View the archives